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Summary: 
Tumour necrosis factor receptor-associated periodic syndrome (TRAPS) is an hereditary 
autoinflammatory disorder characterised by recurrent episodes of fever and inflammation. It is 
associated with autosomal dominant mutations in TNFRSF1A, which encodes tumour necrosis 
factor receptor-1 (TNFR1). Our aim was to understand the influence of TRAPS mutations on 
the response to stimulation of the pattern recognition receptor TLR9.  Peripheral blood 
mononuclear cells (PBMCs) and serum were isolated from TRAPS patients and healthy 
controls: Serum levels of fifteen pro-inflammatory cytokines were measured to assess the initial 
inflammatory status.  IL-1β, IL-6, IL-8, IL17, IL22, TNF-α, VEGF,  IFN-γ, MCP-1 and TGF-
β were significantly elevated in TRAPS patients sera, consistent with constitutive inflammation. 
Stimulation of PBMCs with TLR9 ligand (ODN2006) triggered significantly greater 
upregulation of pro-inflammatory signalling intermediates (TRAF3, IRAK2, TOLLIP, TRAF6, 
pTAK, TAB2, pTAB2, IRF7, RIP, NF-kB p65, pNF-kB p65, and MEK1/2) in TRAPS patients’ 
PBMCs. This upregulation of proinflammatory signalling intermediates and raised serum 
cytokines occurred despite concurrent anakinra treatment and no overt clinical symptoms at 
time of sampling. These novel findings further demonstrate the wide-ranging nature of the 
dysregulation of innate immune responses underlying the pathology of TRAPS and highlights 
the need for novel pathway-specific therapeutic treatments for this disease. 
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Introduction: 
The rare autoinflammatory disease, Tumour Necrosis Factor Receptor Associated Periodic 
Syndrome (TRAPS) is caused by autosomal dominant missense mutations in the TNFRSF1A 
gene, encoding TNFR1 1. TRAPS patients demonstrate exaggerated innate immune 
responsiveness  and are characterised clinically by recurrent prolonged episodes of fever, 
migratory rash, peritonitis, myalgia, and arthralgia, with systemic amyloidosis occurring in  a 
proportion of patients 2. Intracellular aggregation of mutant TNFR1 plays a major role in the 
pathogenesis of TRAPS through a variety of mechanisms including: misfolding and ligand-
independent signalling, an unfolded protein response, induction of reactive oxygen species 
(ROS) and impaired autophagy 3, 4. Both transfected cells and TRAPS patients’ PBMCs 
expressing a prototypic TRAPS-related mutant TNFR1 (C33Y), reveal perturbations and 
activation of multiple pro-inflammatory signalling pathways5. Thus, mutant TNF receptors 
create an intracellular environment  conducive to drive chronic inflammation and  synergy 
between mutant and wild-type TNFR1 actions is required to generate the full TRAPS phenotype 
6, 7.  
An area of increasing interest is the cross-talk between mutant TNFRs and pattern recognition 
receptors (PRRs), including the Toll-like receptors (TLRs) involved in innate immune 
activation. It has recently been proposed that cells with TRAPS-related mutant TNFR display 
greater sensitivity to PRR ligands such as the TLR4 ligand, bacterial lipopolysaccharide (LPS),  
due to excessive activation of downstream signalling through the mitogen-activated protein 
kinases (MAPKs), resulting in enhanced  production of pro-inflammatory cytokines 8.  
TLR9 is an endosomal PRR which recognises unmethylated CpG-rich DNA motifs, 
frequently found in bacterial, mitochondrial and viral DNA. TLR9 activation initiates innate 
immune responses via the adaptor molecule MyD88, and subsequently IRAK4 and TRAF6, 
and ultimately activation of IRF7, NFkB, JNK and P38 MAP kinases, ultimately leading to the 
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production of inflammatory cytokines and type 1 interferons9.  
This study investigates how the host innate immune response to TLR9-stimulation is 
influenced by the TRAPS-associated C33Y mutant TNFR1 (TNFR1(C33Y)). Venous blood from 
patients with TNFR1(C33Y) and controls were examined for serum cytokine levels to establish 
baseline levels of inflammatory mediators, and the  TLR9 agonist (ODN2006) was used to 
stimulate isolated peripheral blood mononuclear cells (PBMCs) from both sample groups and 
the  expression and activation of pro-inflammatory signalling pathways was subsequently 
evaluated using protein microarray technologies 10.   
Material and Methods:  
Patients and Healthy Controls:  
Four TRAPS patients carrying TNFR1(C33Y) [2 males, 2 females; mean age of 46.3 (range 33-66)] 
and five healthy controls [2 males,3 females; mean age of 43.5 (range 27-62)] were included 
for TLR9 signalling pathway studies in PBMCs. For cytokine assays, seven controls sera [3 
males, 4 females; mean age of 48 (range 27-62)] were compared to the patients’ samples. All 
TRAPS patients were being treated with anakinra and none had any clinical symptoms of 
inflammation at the time of blood sampling.  
Serum collection and PBMC separation: 
Blood samples were collected after ethical approval and with informed consent, into citrate 
phosphate dextrose (ACD; Baxter Health Care, Norfolk, UK) and processed within 2h of 
sampling. PBMCs were isolated by ficoll-density gradient centrifugation. PBMCs were 
resuspended in serum-free RPMI 1640, containing 25mM HEPES and L-glutamine, at a density 
of 2x105 cells/ml. Cells were exposed to 5µM ODN 2006 (InvivoGen, Toulouse, FR) for 2h, 
cells were then washed with ice-cold PBS, pelleted and lysed with 100 µl of RIPA lysis buffer 
containing 5 units/ml benzonase nuclease (Sigma-Aldrich, UK) and 1X Halt™ Protease and 
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Phosphatase Inhibitor Cocktail (Fisher Scientific, UK) for 20m with continuous agitation on 
ice.  
TLR9 expression in PBMCs from TRAPS and healthy controls: 
Cells were stained for flow cytometry as previously described 11 to evaluate TLR9 expression. 
Following washing with PBA (PBS / 1% BSA / 0.05% NaN3), the PBMCs were 
permeabilised using saponin buffer and stained for 2h in the dark with anti-human CD289 
(TLR9) PE or appropriate isotype controls (rat IgG2a PE) (e-Bioscience). Cells were then 
washed twice in PBA,  resuspended in 0.5% formaldehyde fixative and analysed on a Coulter 
FC500 flow cytometer. Analysis was performed using WEASEL software (Walter and Eliza 
Hall Institute, Parkville, Australia). 
 
Reverse Phase Protein Arrays (RPPA) analysis:  
RPPA was used as optimised and validated previously5. Briefly, PBMC lysates were diluted 
3+1 with 4x SDS sample buffer (278mM Tris.Cl, Ph 6.8, 44% glycerol, 4.4% SDS, 8% 2-
mercaptoethanol) and heated (95°C for 5minutes). Samples were spotted in quadruplicate onto 
nitrocellulose-coated glass slides (Grace Bio-labs) with a MicroGrid II robot (BioRobotics Inc., 
USA). The printed slides were blocked overnight at 4°C in blocking solution (0.2% I-block 
(Tropix, Bedford, MA, USA), 0.1% Tween-20 in PBS) at 4°C. After washing three times for 5 
minutes each in PBS,+0.05% Tween-20 (PBST), the slides were incubated overnight at 4°C 
with the specific primary antibodies (Cell Signaling Technology, USA). Supplementary table 
1S shows the details of the primary antibodies used for RPPA analysis. b-actin antibody was 
used as a housekeeping protein to control protein loading. After washing in PBST (3x), primary 
antibody detection was achieved using infrared Licor secondary antibodies (800-CW anti-rabbit 
antibody and 700-CW anti-mouse antibody) for 30 minutes at room temperature in the dark 
with shaking. After washing in PBST 3x and rinsing in water, arrays were centrifuged to dry, 
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and scanned with a Licor Odyssey SA scanner (LI-COR Biosciences, UK) at 20 µm resolution. 
Fluorescence images were processed with Axon Genepix Pro-6 Microarray Image Analysis 
software (Axon Instruments Inc.). Target signals were finally determined after background 
subtraction and normalization to the internal housekeeping targets using RPPanalyzer, a module 
within the R statistical language 12. The specificity of all the primary antibodies was verified 
using gel electrophoresis and western blotting as described previously 13. Only antibodies 
detecting single bands of the correct molecular weight target were used. 
Cytokine analysis: 
Cytokines were analysed in sera from TRAPS patients and controls using antibody microarray 
based sandwich ELISA. DuoSet paired antibody kits (R&D Systems, Minneapolis, MN) were 
used for the detection of 16 cytokines: eotaxin-1, eotaxin-2, IFN-γ, IL-1β, IL-4, IL-6, IL-8, 
IL-10, IL-17, IL-22, MCP-1, RAGE, TGF-β , TNF-α , and VEGF 10. In brief, capture 
antibodies were printed at 100 µg/mL in quadruplicate as regular arrays (16 per slide) onto 
poly-L-lysine-coated glass slides (Thermo-Fisher, UK) using a MicroGrid II robot. The array 
slides were blocked with I-Block (0.2% in PBS) for 1h and washed three times with PBST. A 
cocktail of recombinant cytokine standards was prepared with each cytokine at the maximum 
recommended standard curve concentration, and then used to generate eight doubling dilutions. 
Standard dilutions and samples were added to independent arrays for 1h at room temperature 
with frequent shaking followed by three washes with PBST. A mixture of the manufacturers 
biotinylated detection antibodies was added at the recommended concentrations to each array 
for 1h with shaking. After washing with PBST as before, A 1:1:300 mixture of Genisphere 
Streptavidin 3DNA Oyster 650-40 : Nucleic Acid Blocker (Genisphere UltraAmp, UK): 
Antibody diluent (Dako, Ely, UK was added and incubated for 30 minutes at room temperature 
with frequent shaking in the dark. Slides were then washed three times with PBST, rinsed with 
ultra-pure water and dried by centrifugation. Slides were scanned at 635 nm with a Genepix 
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4200AL scanner (Axon Instruments) and fluorescence signals quantified using Axon Genepix 
Pro-6 software. The concentration of each cytokine in samples was subsequently extrapolated 
from the standard curve values.  
 
Statistical analysis:  
Statistical analyses were performed using GraphPad Prism 6 software. One-way ANOVA and 
Bonferroni’s multiple comparisons test was undertaken to compare signalling molecules 
expression in different conditions. The statistical differences in cytokine expression and TLR9 
expression between patient and control samples were determined by Mann-Whitney test.  
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Results:  
In vivo constitutive inflammatory stimulation in TRAPS patients:  
Fifteen inflammatory cytokines and chemokines was measured in the sera of TRAPS 
patients with TNFR1(C33Y)  and age/sex-matched healthy controls to determine the underlying 
inflammatory status of each patient at the time of PBMC collection (Figure 1). 
Significantly higher levels of the following cytokines were observed in TRAPS patients 
compared to the healthy controls: IL-1β, IL-6, IL-8, IL-17, IL-22, TNF-α, VEGF,  IFN-γ, 
MCP-1 and TGF-β (Figure 1a,c,d,f,g,h,i,m and o). Eotaxin-1, RAGE, IL-10 and IL-4 were 
not significantly different between the groups (Figure 1b,e,n) and eotaxin-2 was 
significantly higher in the controls (Figure 1k). These findings support and extend previous 
studies14-17 by revealing the presence of additional pro-inflammatory serum 
cytokines/chemokines (IFN-γ, IL17, IL22 and MCP1) in TRAPS patients and also 
increased serum TGF-β and VEGF.  
Ex vivo constitutive activation of inflammatory pathways in TRAPS patients: 
TRAPS patients’ PBMCs in the absence of external stimulation have already been shown 
to exhibit enhanced activation of pro-inflammatory signalling pathways 13. In this study, we 
therefore investigated the influence of TNFR1(C33Y)  on responses to  TLR9 stimulation isolate 
PBMCs. Binding of the synthetic agonist ODN2006 to TLR9 triggers a complex series of 
intracellular signal transduction events9. Concurrent evaluation of target protein expression 
and activation related post-translational modifications were measured using reverse-phase 
protein arrays. PBMCs from TRAPS patients with TNFR1(C33Y) and from healthy controls 
were cultured with or without ODN2006, lysed and 49 signalling intermediates, including 
Deleted: 14, 1514-17
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TLR9 pathway-associated molecules were subsequently measured. b-actin abundance was 
measured as a normalizing protein control. Supplementary table 1S shows the list of the 
primary antibodies used in this study. Comparisons were then made between the TNFR1(C33Y) 
patient samples and control samples, both before and after ODN2006 stimulation (Figure 
2).  Table 1 (column A) shows that 36 out of the 49 signalling molecules measured revealed 
significantly higher baseline levels in untreated TRAPs patients’ PBMCs compared to 
untreated PBMCs of healthy controls.   Similarly, comparison of ODN2006-stimulated 
PBMCs revealed 42/49 signalling molecules detected at significantly higher levels in 
patients’ PBMCs compared to healthy controls (table 1, column B).   However, the most 
important finding derives from comparisons between ODN2006-stimulated PBMCs and 
unstimulated cells: for the TRAPS patients, 17/49 signalling molecules were significantly 
raised by stimulation with ODN2006 (table 1, column C), but only 4/49 signalling 
molecules were significantly raised in the healthy control PBMCs, only one of which 
(IRAK4) was not also up-regulated in the patients’ cells (table 1, column D).   
 
TLR 9 expression in PBMCs from TRAPS patients and healthy controls:  
To establish whether the hypersensitivity of the TLR9-stimulated response seen the 
TNFR1(C33Y) patients PBMCs might be due to differential TLR9 expression, we compared 
TLR9 expression in PBMCs of patients and healthy controls by intracellular staining and 
flow cytometry. There was no significant difference in TLR9 expression between the two 
groups as measured by the mean fluorescence intensity (MFI) or the percentage of TLR9 
positive cells (supplementary figure 1S).  Thus, the hypersensitivity of the TRAPS patients’ 
PBMCs to ODN2006 is not due to increased levels of TLR9. 
 11 
Discussion:  
TRAPS and the other autoinflammatory diseases reflect primary dysfunctions of innate 
immunity, with increasing support suggesting a complex interplay of inflammatory 
signals and inflammasome involvement resulting in the clinical presentations seen18, 19.  We 
hypothesised that the effects of the TRAPS mutant TNFR1 and any subsequent  TLR 
activation (TLR9 used here), may synergise to exacerbate pro-inflammatory responses in 
TRAPS.  
The TRAPS patients studied, all heterozygous for TNFR1(C33Y) ,  were on anakinra (IL-1 
receptor antagonist) therapy at the time of sampling and were without clinical symptoms 
of inflammation.   These patients nevertheless demonstrate increased serum levels of 
multiple pro-inflammatory cytokines, including IL1-b, IL6, IL8 and TNF-a  relative to 
healthy controls samples. The elevated levels of IL1-b seen also give further support to 
the role of inflammasome activation and IL1-b release in TRAPS, as with many other 
autoinflammatory diseases18, 20, and emphasizes the usefulness of therapeutics targeting IL1 
responses, despite TRAPS being a TNFR1mutation-associated disease21. 
In addition our results also revealed increased serum levels of Interferon-g, IL17 and 
IL22, suggestive of additional pro-inflammatory responses, most likely from NK and T 
cell populations22 and of VEGF and the pleotrophic cytokine TGF-b, although their 
relevance in TRAPS disease pathology is currently unclear.  The raised levels of MCP1 
seen in patients may be a consequence of the elevated IL1-b, IL6 and TNF-a and may 
have some bearing on muscle inflammation in TRAPS23, 24. Our findings from patient sera 
therefore highlight the complexity of the constitutive inflammatory status of TRAPS 
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patients, even when clinically well and maintained on a cytokine neutralization therapy 
that does not target the central disease mechanisms 16. 
TLR9-ligation by appropriate DNA ligands leads to stimulation of IRF7, NFkB, JNK and 
P38 MAP kinase pathways, and can also prime the NLRP3 inflammasome by increasing 
expression of both NLRP3 and pro-IL1-b.  Similar expression levels of TLR9 in PBMCs 
from TRAPS patients and healthy controls were observed, however heightened 
expression and activation  of intracellular signaling molecules are seen in PBMCs of the 
TNFR1(C33Y) patients.  These include, as expected, molecules involved in the TLR9 signal 
transduction,  including key adaptors such as TRAF6 and, as we have reported before, 
many elements of the NFkB associated with TNFR1 signalling (figure 2, I  and fig 2, II 
k,i,o ). Phosphorylation of many of these molecules is linked with activation status. The 
increased levels of phosphorylated IRF7, Tak and Tab2, the IKK’s and NFkB P65 
(examples shown in figure 2(II) i,d,g,j and o) indicates that TLR9 stimulation can further 
increase activation of the associated pathways from an already above supra-normal level 
of activity in PBMCs of TRAPS patients.  The evidence that numerous other signalling 
intermediates are also further stimulated suggests that the TNFR1(C33Y)  mutation has a 
wide-ranging influence on cross-talk and activation of pro-inflammatory pathways. 
This study therefore highlights the effect of TLR9 activation in cells expressing the 
TNFR1(C33Y)  mutation.  The TRAPS patients’ PBMCs demonstrate a constitutive pro-
inflammatory state of activation, but are also much more sensitive than those of healthy 
controls to activation of pro-inflammatory signalling pathways via stimulation of TLR9.  
This hypersensitivity, like that reported for the TLR4 ligand LPS 7  could partly explain 
the seemingly spontaneous inflammatory attacks seen in TRAPS, may be triggered by 
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subclinical infections and TLR or possibly other PRR stimulation, that would go 
unnoticed in normal individuals.     
Despite being subject to IL1-neutralizing therapy (anakinra) prior to and at the 
time of sampling, patients showed considerable serum levels of multiple pro-
inflammatory mediators, including IL1-b, IL6, IL8, IL17, IL22 and TNF-a  indicating 
that the underlying effects of TNFR1(C33Y)  mediated dysregulation are largely unchecked as 
a result of treatment13. The extensive signaling activation seen intracellularly in patients 
PMBCs, in both the absence and presence of TLR9 stimulation, does however suggests 
that suppressing such activity may require direct targeting of pathway components which 
lie at convergent points, such as has been suggested for TAB1&2/TAK1 complex25, 
inhibition of the NLRP3 inflammasome18, 26 or further novel targets27, 28.  
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Table 1: Statistical evaluation of intracellular signalling molecule expression in 
PBMCs from TRAPS patients and healthy controls without and with ODN2006 
treatment.   
Table showing statistical comparison (one-way ANOVA with Bonferroni’s multiple 
comparison test) of patient and control group normalised signal intensities of 49 
signalling molecules, measured by  RPPA, with and without ODN2006 stimulation. 
Significant differences between the patient and control group are reported (p values 
<0.05).  Detailed data are shown in figure 2;. A) Patients US (unstimulated patients’ 
PBMCs) vs. Controls US (unstimulated healthy controls’ PBMCs). B) Patients ODN 
(ODN2006-stimulated patients’ PBMCs) vs. Controls ODN (ODN2006-stimulated 
healthy controls’ PBMCs). C) Patients ODN vs. Patients US. D) Controls ODN vs. 
Controls US. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Signalling 
molecule 
A) Patients US vs. 
Controls US 
B) Patients ODN vs. 
Controls ODN 
C)  Patients ODN vs.   
Patients US 
D)  Controls ODN vs. 
Controls US 
MyD88     
TRAF3 0.0001 < 0.0001 0.002  
IRAK-4 0.0052   0.0273 
pIRAK-4      
IRAK-1 < 0.0001 < 0.0001   
IRAK-2 0.0048 < 0.0001 0.0003 0.0425 
IRAK-M     
TOLLIP < 0.0001 < 0.0001 < 0.0001 < 0.0001 
TRAF6 < 0.0001 < 0.0001 0.0132  
pTAK < 0.0001 < 0.0001 0.0115  
TAB2   0.0007 0.0336  
pTAB2 0.0011 < 0.0001             0.0150 
 
 
TBK-NAK  0.0009   
pTBK-NAK     
IRF7 0.0028 < 0.0001 0.0028  
pIRF7 0.0222 0.0054   
IRF3 0.0037 0.0002 0.0428  
pIRF3 < 0.0001 < 0.0001   
TRAF2 0.0123 0.0006   
RIP 0.0003 < 0.0001 0.0107  
pRIP  0.0106   
IKB-alpha 0.0003 < 0.0001   
pIKK-alpha 0.0001 < 0.0001   
NF-KB p65 0.0004 < 0.0001 0.0216  
pNF-κB p65 < 0.0001 < 0.0001 0.0455  
PIKK-gamma 0.0178 0.0014   
PIKK-beta 0.0006 0.0005   
NF-KB p50 0.0013 0.002   
A20  0.0105   
MEK1/2   0.0276 0.0063 
pMEK1/2 < 0.0001 < 0.0001   
pP38  0.0057   
pERK1/2 0.0311    
MKK7  0.0028   
pSEK1/MKK4  0.0022   
pHSP27 < 0.0001 < 0.0001   
pROS 0.0016 < 0.0001   
pATF 0.0169 < 0.0001 0.0109  
pCRAF 0.0071 0.0015   
pAKT Thr 0.0002 < 0.0001 0.0078  
pAKT Serine < 0.0001 < 0.0001   
pPDK1 0.0035 0.0001   
pGSK-3B < 0.0001 < 0.0001   
PI3K110 0.0039 0.0014   
PI3KP85 0.0004 < 0.0001   
CIAP  0.0041 0.025  
ICAM 0.0014 < 0.0001 0.0174  
MMP12 < 0.0001 < 0.0001   
Caspase 8 0.0001 < 0.0001   
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Figure Legends: 
FIGURE 1: Serum cytokine levels  in TRAPS patients and healthy controls.  
The data are shown for individual serum samples (4 TRAPS patients and 7 healthy controls, 
with three technical replicates per sample).  Horizontal bars indicate the mean values. 
Mann-Whitney test was performed and p < 0.05 was considered statistically significant. 
 
Figure 2: Inflammatory signalling pathway intermediates measured by RPPA in 
PBMCs of TRAPS patients and controls.  I) Heat-map columns represent control 
samples (C1-5) and Patient samples (P1-4) either Unstimulated (US) or ODN2006 
stimulated (ODN).  Individual rows represent the signalling molecules studied. 
Antibodies usedand working dilutions are described in full in table 1S. The white to 
Black heat-map colour range represents RPPA signal data normalised to represent 
percentages of the signal range for each molecule examined (0-100%).  Letters a-r at the 
left-hand side refer to the scatter plots in section II of the figure.  II) Scatter plots 
representing actin-normalized relative abundance of selected target proteins which show 
statistically significant differences in columns C and D of table 1. Data are shown for 
individual PBMC lysates (mean of four technical replicates per sample) of four patient 
samples and five control samples. Signals are presented as arbitrary fluorescence units 
after background subtraction and normalization to β-actin. The four conditions were: 
Unstimulated healthy controls’ PBMCs ;Con (US), unstimulated patients’ PBMCs; Pat 
(US), ODN2006-stimulated healthy controls’ PBMCs; Con (ODN) and ODN2006-
stimulated patients’ PBMCs; Pat (US) . Significant differences between conditions for 
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each signalling molecule were determined by one-way ANOVA and Bonferroni's 
multiple comparisons test; these are presented in table 1. 
Figure 3: Visual depiction of findings:  the graphic represents elements of the common 
pathways active by both TNFR1 signalling and signalling through TLR9.  Arrows 
indicate activation route of molecules in the pathways.  Red arrows indicate those 
pathways which are found to be both more abundant and more activated as a result of the 
C33Y TRAPS mutation and also further stimulated by TLR9 ligation as ODN2006 as an 
artificial activator.   Molecules depicted in grey were not studied. 
 
 
 
 
 
 
 
 
